GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders.
GeneVentiv Therapeutics has raised $2.5M in total funding. The most recent round was Grant. The last funding was announced in April 2024.
GeneVentiv Therapeutics's investors include National Heart, Lung and Blood Institute, Innovate Carolina.
GeneVentiv Therapeutics is headquartered in Raleigh, United States.
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on blood diseases and disorders.
GeneVentiv Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GeneVentiv Therapeutics — Funding & Investors." VCBacked, April 16, 2024, https://www.vcbacked.co/company/geneventiv-therapeutics. Accessed October 1, 2026.
VCBacked. (2024). GeneVentiv Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/geneventiv-therapeutics
{{cite web |title=GeneVentiv Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/geneventiv-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated